Pharmacokinetics and Pharmacodynamics of Murepavadin in Neutropenic Mouse Models.
Animals
Anti-Bacterial Agents
/ pharmacokinetics
Area Under Curve
Bacterial Outer Membrane Proteins
/ antagonists & inhibitors
Cross Infection
/ drug therapy
Disease Models, Animal
Mice
Microbial Sensitivity Tests
Neutropenia
/ drug therapy
Peptides, Cyclic
/ pharmacokinetics
Pseudomonas Infections
/ drug therapy
Pseudomonas aeruginosa
/ drug effects
murepavadin
pharmacodynamics
pharmacokinetics
Journal
Antimicrobial agents and chemotherapy
ISSN: 1098-6596
Titre abrégé: Antimicrob Agents Chemother
Pays: United States
ID NLM: 0315061
Informations de publication
Date de publication:
03 2019
03 2019
Historique:
received:
11
08
2018
accepted:
01
01
2019
pubmed:
16
1
2019
medline:
13
2
2020
entrez:
16
1
2019
Statut:
epublish
Résumé
Murepavadin (POL7080) represents the first member of a novel class of outer membrane protein-targeting antibiotics. It specifically interacts with LptD and inhibits lipopolysaccharide (LPS) transport. Murepavadin is being developed for the treatment of serious infections by
Identifiants
pubmed: 30642931
pii: AAC.01699-18
doi: 10.1128/AAC.01699-18
pmc: PMC6395900
pii:
doi:
Substances chimiques
Anti-Bacterial Agents
0
Bacterial Outer Membrane Proteins
0
Peptides, Cyclic
0
murepavadin
0D02GRY87Z
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
Copyright © 2019 American Society for Microbiology.
Références
Science. 2010 Feb 19;327(5968):1010-3
pubmed: 20167788
Clin Microbiol Infect. 2012 Mar;18(3):268-81
pubmed: 21793988
J Antimicrob Chemother. 2015 Dec;70(12):3291-7
pubmed: 26318190
Clin Pharmacokinet. 2011 Nov 1;50(11):689-704
pubmed: 21973267
J Infect. 2015 Mar;70(3):213-22
pubmed: 25445887
Antimicrob Agents Chemother. 2014 May;58(5):2964-7
pubmed: 24566183
Clin Infect Dis. 2010 Aug 1;51 Suppl 1:S81-7
pubmed: 20597676
Antimicrob Agents Chemother. 2008 Jan;52(1):24-36
pubmed: 17846133
Curr Opin Chem Biol. 2017 Jun;38:45-51
pubmed: 28319811
Clin Infect Dis. 2014 Jul 1;59(1):51-61
pubmed: 24723282
Am J Respir Crit Care Med. 2005 Feb 15;171(4):388-416
pubmed: 15699079
Crit Care. 2015 May 06;19:219
pubmed: 25944081
Expert Rev Anti Infect Ther. 2018 Apr;16(4):259-268
pubmed: 29451043
Clin Infect Dis. 2010 Aug 1;51 Suppl 1:S150-70
pubmed: 20597666
Antimicrob Agents Chemother. 2018 Jun 26;62(7):
pubmed: 29686157
Intensive Care Med. 2013 Apr;39(4):682-92
pubmed: 23370828
Diagn Microbiol Infect Dis. 2010 Oct;68(2):140-51
pubmed: 20846586
ACS Chem Biol. 2018 Mar 16;13(3):666-675
pubmed: 29359918
Infect Drug Resist. 2016 Jan 20;9:7-18
pubmed: 26855594
Mol Med Rep. 2018 Dec;18(6):4951-4959
pubmed: 30280189
Antimicrob Agents Chemother. 2018 Mar 27;62(4):
pubmed: 29437621
Crit Care. 2016 Jan 29;20:19
pubmed: 26821535
J Pharm Pharmacol. 1987 Aug;39(8):599-603
pubmed: 2888849
Public Health Rep. 2007 Mar-Apr;122(2):160-6
pubmed: 17357358
Crit Care Med. 2014 Oct;42(10):2178-87
pubmed: 25054674
J Antimicrob Chemother. 2018 Sep 1;73(9):2400-2404
pubmed: 29901750